These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18309874)

  • 21. Primary prevention of cardiovascular disease in people with dysglycemia.
    Bianchi C; Miccoli R; Penno G; Del Prato S
    Diabetes Care; 2008 Feb; 31 Suppl 2():S208-14. PubMed ID: 18227487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Glitazones critically evaluated].
    Schernthaner G
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
    [No Abstract]   [Full Text] [Related]  

  • 23. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
    Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
    Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes.
    Roman G; Hancu N
    Horm Metab Res; 2009 Feb; 41(2):116-22. PubMed ID: 19214921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials.
    Charbonnel B
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():19-20. PubMed ID: 18001315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sulfonylureas and the risk of myocardial infarction.
    Thisted H; Johnsen SP; Rungby J
    Metabolism; 2006 May; 55(5 Suppl 1):S16-9. PubMed ID: 16631805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Oral antidiabetic drugs. How to begin and combine without cardiovascular risk].
    Duarte R
    Rev Port Cardiol; 2013 Apr; 32 Suppl 1():15-24. PubMed ID: 23721975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cardioprotection by acarbose--contra].
    Kaiser T; Sawicki PT
    Dtsch Med Wochenschr; 2004 May; 129(20):1156. PubMed ID: 15143460
    [No Abstract]   [Full Text] [Related]  

  • 29. [Late diagnosis. Only after infarct is diabetes detected].
    MMW Fortschr Med; 2004 Jan; 146(5):51. PubMed ID: 15035427
    [No Abstract]   [Full Text] [Related]  

  • 30. Metformin: diamonds are forever.
    Papanas N; Maltezos E; Mikhailidis DP
    Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.
    Nathanson D; Nyström T
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):112-26. PubMed ID: 19038307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Redefining quality--implications of recent clinical trials.
    Krumholz HM; Lee TH
    N Engl J Med; 2008 Jun; 358(24):2537-9. PubMed ID: 18539915
    [No Abstract]   [Full Text] [Related]  

  • 33. Glycemic targets for patients with type 2 diabetes mellitus.
    Hamnvik OP; McMahon GT
    Mt Sinai J Med; 2009 Jun; 76(3):227-33. PubMed ID: 19421966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does intensive glycemic control improve cardiovascular outcomes?
    Pendergrass M
    Nat Clin Pract Endocrinol Metab; 2008 Oct; 4(10):529. PubMed ID: 18806805
    [No Abstract]   [Full Text] [Related]  

  • 35. [Insulin treatment in type 2 diabetes].
    Birkeland KI
    Tidsskr Nor Laegeforen; 2006 Mar; 126(7):919-20. PubMed ID: 16554885
    [No Abstract]   [Full Text] [Related]  

  • 36. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
    Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Lamanna C; Gensini GF; Marchionni N
    Diabetes Obes Metab; 2008 Dec; 10(12):1221-38. PubMed ID: 18505403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guidelines improve general trend of lowered cholesterol levels in type 2 diabetes patients in spite of low adherence.
    Fhärm E; Rolandsson O; Weinehall L
    Scand J Public Health; 2008 Jan; 36(1):69-75. PubMed ID: 18426787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.